Henlius and Sandoz Expand Biosimilars Partnership with $322M Deal — Shanghai Henlius Biotech, Inc.

Event summary

Henlius and Sandoz have expanded their 2025 oncology biosimilars partnership to cover up to 10 proposed monoclonal antibody and antibody-drug conjugate biosimilar assets.
The deal includes an upfront payment, milestone payments, and a non-refundable option fee totaling up to $322 million, with $100.5 million expected in 2026.
Initial assets include HLX05-N (cetuximab biosimilar), HLX16 (evolocumab biosimilar), and a belimumab biosimilar, with Sandoz obtaining an option for HLXTE-HAase1001.
Henlius will handle development, manufacturing, and supply, while Sandoz will manage registration, market access, and commercialization outside China.
The collaboration territory for HLX05-N includes the U.S., EU, Japan, and other regions, with exclusive rights for HLX16 and the belimumab biosimilar worldwide outside China.

The big picture

This collaboration underscores Henlius' strategy to globalize its biosimilars platform, leveraging Sandoz's commercialization expertise to tap into high-value markets. The deal reflects a broader industry trend of partnerships between biotech innovators and established generics players to accelerate biosimilar development and market entry. With biosimilars representing a growing share of the biologics market, the success of this partnership could set a precedent for similar collaborations.

What we're watching

Development Timelines: The pace at which Henlius and Sandoz can advance the early-stage biosimilar assets through development and regulatory approvals will determine the deal's success.
Market Penetration: Whether Sandoz can effectively leverage its global footprint to commercialize these biosimilars in key markets outside China.
Strategic Flexibility: How Henlius balances independent commercialization efforts with strategic partnerships to maximize global market access.